Compare ELMD & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | SABS |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 201.4M |
| IPO Year | 2010 | N/A |
| Metric | ELMD | SABS |
|---|---|---|
| Price | $23.07 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $36.00 | $9.80 |
| AVG Volume (30 Days) | 42.6K | ★ 654.4K |
| Earning Date | 02-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $41.86 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $1.00 |
| 52 Week High | $30.73 | $6.60 |
| Indicator | ELMD | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 43.61 |
| Support Level | $17.87 | $3.52 |
| Resistance Level | $25.38 | $4.16 |
| Average True Range (ATR) | 0.76 | 0.30 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 16.67 | 6.62 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.